REPORT ID 2782

Asia-Pacific Amyloidosis Therapeutics Market Report 2017

Publish Date
11-Dec-17
Pages
112
Format
Electronic (PDF)

In this report, the Asia-Pacific Amyloidosis Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Amyloidosis Therapeutics for these regions, from 2012 to 2022 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

Asia-Pacific Amyloidosis Therapeutics market competition by top manufacturers/players, with Amyloidosis Therapeutics sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Pfizer Inc.
    ProteoTech, Inc.
    Alnylam Pharmaceuticals, Inc.
    Arcturus Therapeutics, Inc
    Bellus Health Inc.
    Bsim2
    Celgene Corporation
    Millennium Pharmaceuticals, Inc.
    Onyx Pharmaceuticals, Inc.
    GlaxoSmithKline Plc
    Isis Pharmaceuticals, Inc.
    Prothena Corporation Plc
    SOM Innovation Biotech SL

On the basis of product, this report displays the sales volum, revenue, product price, market share and growth rate of each type, primarily split into
    AG-10
    ALN-ANG
    ALN-TTRsc02
    CAEL-101
    canakinumab
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    AL amyloidosis
    AA amyloidoses
    ATTR amyloidoses
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Asia-Pacific Amyloidosis Therapeutics Market Report 2017
1 Amyloidosis Therapeutics Overview
    1.1 Product Overview and Scope of Amyloidosis Therapeutics
    1.2 Classification of Amyloidosis Therapeutics by Product Category
        1.2.1 Asia-Pacific Amyloidosis Therapeutics Market Size (Sales) Comparison by Types (2012-2022)
        1.2.2 Asia-Pacific Amyloidosis Therapeutics Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 AG-10
        1.2.4 ALN-ANG
        1.2.5 ALN-TTRsc02
        1.2.6 CAEL-101
        1.2.7 canakinumab
        1.2.8 Others
    1.3 Asia-Pacific Amyloidosis Therapeutics Market by Application/End Users
        1.3.1 Asia-Pacific Amyloidosis Therapeutics Sales (Volume) and Market Share Comparison by Applications (2012-2022)
        1.3.2 AL amyloidosis
        1.3.3 AA amyloidoses
        1.3.4 ATTR amyloidoses
        1.3.5 Others
    1.4 Asia-Pacific Amyloidosis Therapeutics Market by Region
        1.4.1 Asia-Pacific Amyloidosis Therapeutics Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 China Status and Prospect (2012-2022)
        1.4.3 Japan Status and Prospect (2012-2022)
        1.4.4 South Korea Status and Prospect (2012-2022)
        1.4.5 Taiwan Status and Prospect (2012-2022)
        1.4.6 India Status and Prospect (2012-2022)
        1.4.7 Southeast Asia Status and Prospect (2012-2022)
        1.4.8 Australia Status and Prospect (2012-2022)
    1.5 Asia-Pacific Market Size (Value and Volume) of Amyloidosis Therapeutics (2012-2022)
        1.5.1 Asia-Pacific Amyloidosis Therapeutics Sales and Growth Rate (2012-2022)
        1.5.2 Asia-Pacific Amyloidosis Therapeutics Revenue and Growth Rate (2012-2022)

2 Asia-Pacific Amyloidosis Therapeutics Competition by Players/Suppliers, Region, Type and Application
    2.1 Asia-Pacific Amyloidosis Therapeutics Market Competition by Players/Suppliers
        2.1.1 Asia-Pacific Amyloidosis Therapeutics Sales Volume and Market Share of Key Players/Suppliers (2012-2017)
        2.1.2 Asia-Pacific Amyloidosis Therapeutics Revenue and Share by Players/Suppliers (2012-2017)
    2.2 Asia-Pacific Amyloidosis Therapeutics (Volume and Value) by Type
        2.2.1 Asia-Pacific Amyloidosis Therapeutics Sales and Market Share by Type (2012-2017)
        2.2.2 Asia-Pacific Amyloidosis Therapeutics Revenue and Market Share by Type (2012-2017)
    2.3 Asia-Pacific Amyloidosis Therapeutics (Volume) by Application
    2.4 Asia-Pacific Amyloidosis Therapeutics (Volume and Value) by Region
        2.4.1 Asia-Pacific Amyloidosis Therapeutics Sales and Market Share by Region (2012-2017)
        2.4.2 Asia-Pacific Amyloidosis Therapeutics Revenue and Market Share by Region (2012-2017)

3 China Amyloidosis Therapeutics (Volume, Value and Sales Price)
    3.1 China Amyloidosis Therapeutics Sales and Value (2012-2017)
        3.1.1 China Amyloidosis Therapeutics Sales Volume and Growth Rate (2012-2017)
        3.1.2 China Amyloidosis Therapeutics Revenue and Growth Rate (2012-2017)
        3.1.3 China Amyloidosis Therapeutics Sales Price Trend (2012-2017)
    3.2 China Amyloidosis Therapeutics Sales Volume and Market Share by Type
    3.3 China Amyloidosis Therapeutics Sales Volume and Market Share by Application

4 Japan Amyloidosis Therapeutics (Volume, Value and Sales Price)
    4.1 Japan Amyloidosis Therapeutics Sales and Value (2012-2017)
        4.1.1 Japan Amyloidosis Therapeutics Sales Volume and Growth Rate (2012-2017)
        4.1.2 Japan Amyloidosis Therapeutics Revenue and Growth Rate (2012-2017)
        4.1.3 Japan Amyloidosis Therapeutics Sales Price Trend (2012-2017)
    4.2 Japan Amyloidosis Therapeutics Sales Volume and Market Share by Type
    4.3 Japan Amyloidosis Therapeutics Sales Volume and Market Share by Application

5 South Korea Amyloidosis Therapeutics (Volume, Value and Sales Price)
    5.1 South Korea Amyloidosis Therapeutics Sales and Value (2012-2017)
        5.1.1 South Korea Amyloidosis Therapeutics Sales Volume and Growth Rate (2012-2017)
        5.1.2 South Korea Amyloidosis Therapeutics Revenue and Growth Rate (2012-2017)
        5.1.3 South Korea Amyloidosis Therapeutics Sales Price Trend (2012-2017)
    5.2 South Korea Amyloidosis Therapeutics Sales Volume and Market Share by Type
    5.3 South Korea Amyloidosis Therapeutics Sales Volume and Market Share by Application

6 Taiwan Amyloidosis Therapeutics (Volume, Value and Sales Price)
    6.1 Taiwan Amyloidosis Therapeutics Sales and Value (2012-2017)
        6.1.1 Taiwan Amyloidosis Therapeutics Sales Volume and Growth Rate (2012-2017)
        6.1.2 Taiwan Amyloidosis Therapeutics Revenue and Growth Rate (2012-2017)
        6.1.3 Taiwan Amyloidosis Therapeutics Sales Price Trend (2012-2017)
    6.2 Taiwan Amyloidosis Therapeutics Sales Volume and Market Share by Type
    6.3 Taiwan Amyloidosis Therapeutics Sales Volume and Market Share by Application

7 India Amyloidosis Therapeutics (Volume, Value and Sales Price)
    7.1 India Amyloidosis Therapeutics Sales and Value (2012-2017)
        7.1.1 India Amyloidosis Therapeutics Sales Volume and Growth Rate (2012-2017)
        7.1.2 India Amyloidosis Therapeutics Revenue and Growth Rate (2012-2017)
        7.1.3 India Amyloidosis Therapeutics Sales Price Trend (2012-2017)
    7.2 India Amyloidosis Therapeutics Sales Volume and Market Share by Type
    7.3 India Amyloidosis Therapeutics Sales Volume and Market Share by Application

8 Southeast Asia Amyloidosis Therapeutics (Volume, Value and Sales Price)
    8.1 Southeast Asia Amyloidosis Therapeutics Sales and Value (2012-2017)
        8.1.1 Southeast Asia Amyloidosis Therapeutics Sales Volume and Growth Rate (2012-2017)
        8.1.2 Southeast Asia Amyloidosis Therapeutics Revenue and Growth Rate (2012-2017)
        8.1.3 Southeast Asia Amyloidosis Therapeutics Sales Price Trend (2012-2017)
    8.2 Southeast Asia Amyloidosis Therapeutics Sales Volume and Market Share by Type
    8.3 Southeast Asia Amyloidosis Therapeutics Sales Volume and Market Share by Application

9 Australia Amyloidosis Therapeutics (Volume, Value and Sales Price)
    9.1 Australia Amyloidosis Therapeutics Sales and Value (2012-2017)
        9.1.1 Australia Amyloidosis Therapeutics Sales Volume and Growth Rate (2012-2017)
        9.1.2 Australia Amyloidosis Therapeutics Revenue and Growth Rate (2012-2017)
        9.1.3 Australia Amyloidosis Therapeutics Sales Price Trend (2012-2017)
    9.2 Australia Amyloidosis Therapeutics Sales Volume and Market Share by Type
    9.3 Australia Amyloidosis Therapeutics Sales Volume and Market Share by Application

10 Asia-Pacific Amyloidosis Therapeutics Players/Suppliers Profiles and Sales Data
    10.1 Pfizer Inc.
        10.1.1 Company Basic Information, Manufacturing Base and Competitors
        10.1.2 Amyloidosis Therapeutics Product Category, Application and Specification
            10.1.2.1 Product A
            10.1.2.2 Product B
        10.1.3 Pfizer Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.1.4 Main Business/Business Overview
    10.2 ProteoTech, Inc.
        10.2.1 Company Basic Information, Manufacturing Base and Competitors
        10.2.2 Amyloidosis Therapeutics Product Category, Application and Specification
            10.2.2.1 Product A
            10.2.2.2 Product B
        10.2.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.2.4 Main Business/Business Overview
    10.3 Alnylam Pharmaceuticals, Inc.
        10.3.1 Company Basic Information, Manufacturing Base and Competitors
        10.3.2 Amyloidosis Therapeutics Product Category, Application and Specification
            10.3.2.1 Product A
            10.3.2.2 Product B
        10.3.3 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.3.4 Main Business/Business Overview
    10.4 Arcturus Therapeutics, Inc
        10.4.1 Company Basic Information, Manufacturing Base and Competitors
        10.4.2 Amyloidosis Therapeutics Product Category, Application and Specification
            10.4.2.1 Product A
            10.4.2.2 Product B
        10.4.3 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.4.4 Main Business/Business Overview
    10.5 Bellus Health Inc.
        10.5.1 Company Basic Information, Manufacturing Base and Competitors
        10.5.2 Amyloidosis Therapeutics Product Category, Application and Specification
            10.5.2.1 Product A
            10.5.2.2 Product B
        10.5.3 Bellus Health Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.5.4 Main Business/Business Overview
    10.6 Bsim2
        10.6.1 Company Basic Information, Manufacturing Base and Competitors
        10.6.2 Amyloidosis Therapeutics Product Category, Application and Specification
            10.6.2.1 Product A
            10.6.2.2 Product B
        10.6.3 Bsim2 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.6.4 Main Business/Business Overview
    10.7 Celgene Corporation
        10.7.1 Company Basic Information, Manufacturing Base and Competitors
        10.7.2 Amyloidosis Therapeutics Product Category, Application and Specification
            10.7.2.1 Product A
            10.7.2.2 Product B
        10.7.3 Celgene Corporation Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.7.4 Main Business/Business Overview
    10.8 Millennium Pharmaceuticals, Inc.
        10.8.1 Company Basic Information, Manufacturing Base and Competitors
        10.8.2 Amyloidosis Therapeutics Product Category, Application and Specification
            10.8.2.1 Product A
            10.8.2.2 Product B
        10.8.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.8.4 Main Business/Business Overview
    10.9 Onyx Pharmaceuticals, Inc.
        10.9.1 Company Basic Information, Manufacturing Base and Competitors
        10.9.2 Amyloidosis Therapeutics Product Category, Application and Specification
            10.9.2.1 Product A
            10.9.2.2 Product B
        10.9.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.9.4 Main Business/Business Overview
    10.10 GlaxoSmithKline Plc
        10.10.1 Company Basic Information, Manufacturing Base and Competitors
        10.10.2 Amyloidosis Therapeutics Product Category, Application and Specification
            10.10.2.1 Product A
            10.10.2.2 Product B
        10.10.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        10.10.4 Main Business/Business Overview
    10.11 Isis Pharmaceuticals, Inc.
    10.12 Prothena Corporation Plc
    10.13 SOM Innovation Biotech SL

11 Amyloidosis Therapeutics Manufacturing Cost Analysis
    11.1 Amyloidosis Therapeutics Key Raw Materials Analysis
        11.1.1 Key Raw Materials
        11.1.2 Price Trend of Key Raw Materials
        11.1.3 Key Suppliers of Raw Materials
        11.1.4 Market Concentration Rate of Raw Materials
    11.2 Proportion of Manufacturing Cost Structure
        11.2.1 Raw Materials
        11.2.2 Labor Cost
        11.2.3 Manufacturing Expenses
    11.3 Manufacturing Process Analysis of Amyloidosis Therapeutics

12 Industrial Chain, Sourcing Strategy and Downstream Buyers
    12.1 Amyloidosis Therapeutics Industrial Chain Analysis
    12.2 Upstream Raw Materials Sourcing
    12.3 Raw Materials Sources of Amyloidosis Therapeutics Major Manufacturers in 2016
    12.4 Downstream Buyers

13 Marketing Strategy Analysis, Distributors/Traders
    13.1 Marketing Channel
        13.1.1 Direct Marketing
        13.1.2 Indirect Marketing
        13.1.3 Marketing Channel Development Trend
    13.2 Market Positioning
        13.2.1 Pricing Strategy
        13.2.2 Brand Strategy
        13.2.3 Target Client
    13.3 Distributors/Traders List

14 Market Effect Factors Analysis
    14.1 Technology Progress/Risk
        14.1.1 Substitutes Threat
        14.1.2 Technology Progress in Related Industry
    14.2 Consumer Needs/Customer Preference Change
    14.3 Economic/Political Environmental Change

15 Asia-Pacific Amyloidosis Therapeutics Market Forecast (2017-2022)
    15.1 Asia-Pacific Amyloidosis Therapeutics Sales Volume, Revenue and Price Forecast (2017-2022)
        15.1.1 Asia-Pacific Amyloidosis Therapeutics Sales Volume and Growth Rate Forecast (2017-2022)
        15.1.2 Asia-Pacific Amyloidosis Therapeutics Revenue and Growth Rate Forecast (2017-2022)
        15.1.3 Asia-Pacific Amyloidosis Therapeutics Price and Trend Forecast (2017-2022)
    15.2 Asia-Pacific Amyloidosis Therapeutics Sales Volume, Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.1 Asia-Pacific Amyloidosis Therapeutics Sales Volume and Growth Rate Forecast by Region (2017-2022)
        15.2.2 Asia-Pacific Amyloidosis Therapeutics Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.3 China Amyloidosis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.4 Japan Amyloidosis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.5 South Korea Amyloidosis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.6 Taiwan Amyloidosis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.7 India Amyloidosis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.8 Southeast Asia Amyloidosis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.9 Australia Amyloidosis Therapeutics Sales, Revenue and Growth Rate Forecast (2017-2022)
    15.3 Asia-Pacific Amyloidosis Therapeutics Sales, Revenue and Price Forecast by Type (2017-2022)
        15.3.1 Asia-Pacific Amyloidosis Therapeutics Sales Forecast by Type (2017-2022)
        15.3.2 Asia-Pacific Amyloidosis Therapeutics Revenue Forecast by Type (2017-2022)
        15.3.3 Asia-Pacific Amyloidosis Therapeutics Price Forecast by Type (2017-2022)
    15.4 Asia-Pacific Amyloidosis Therapeutics Sales Forecast by Application (2017-2022)

16 Research Findings and Conclusion

17 Appendix
    17.1 Methodology/Research Approach
        17.1.1 Research Programs/Design
        17.1.2 Market Size Estimation
        17.1.3 Market Breakdown and Data Triangulation
    17.2 Data Source
        17.2.1 Secondary Sources
        17.2.2 Primary Sources
    17.3 Disclaimer